GSK Boosts Oncology
GSK Acquires Nuvalent for $10.6 Billion to Expand Cancer Line
GSK has agreed to buy US cancer biotech Nuvalent for $10.6 billion in cash, its largest deal in more than a decade. The all-cash offer of $124 per share represents a 40% premium over Nuvalent's closing price of $88.49 on June 8, according to Bloomberg Law.
The deal gives GSK two lung cancer drugs on the verge of US approval. The FDA is expected to rule on zidesamtinib in September and neladalkib in November. Both drugs target non-small cell lung cancer, the most common form of the disease. The Guardian reports GSK expects each drug to generate several billion dollars in annual sales.
Two Blockbuster Drugs Drive the $10.6 Billion Price Tag
Zidesamtinib and neladalkib are both next-generation tyrosine kinase inhibitors — drugs that block the signals that cause cancer cells to grow. They target patients with ROS1 and ALK gene mutations whose tumors have stopped responding to older treatments. GSK CEO Luke Miels said the drugs fill critical "efficacy and tolerability gaps" in current lung cancer care, according to Bloomberg Government.
The FDA has already granted neladalkib Priority Review, a fast-track status for drugs that may offer major improvements over existing therapies. GSK's net cost after accounting for Nuvalent's existing cash reserves is $9.4 billion. The company says the deal will add to its core earnings per share by 2029.
New CEO Luke Miels Bets Big on Oncology From Day One
Miels took over as GSK chief executive on January 1, 2026, succeeding Dame Emma Walmsley. He has moved fast. In January, GSK bought RAPT Therapeutics for $2.2 billion. In February, it acquired pulmonary hypertension firm 35Pharma for $950 million. The Nuvalent deal, announced just six months into his tenure, is by far the largest. The Guardian notes it is GSK's biggest acquisition since a $20 billion asset swap with Novartis in 2014.
Nuvalent CEO James Porter said GSK's "proven track record, infrastructure, and expertise" would help bring the drugs to market and speed up the rest of their pipeline, according to BSS News.
GSK Rebuilding Oncology to Outrun Patent Cliff
GSK sold off most of its cancer portfolio to Novartis over a decade ago. The company has been slowly rebuilding ever since. Miels is now pushing hard on oncology to offset looming revenue losses from GSK's HIV drug patents, which begin expiring later this decade. The Nuvalent deal is a cornerstone of GSK's target of £40 billion in annual sales by 2031.
GSK also plans to pair Nuvalent's drugs with its own experimental lung cancer treatment, known as Ris-Rez, an antibody drug conjugate that delivers chemotherapy directly to tumor cells. The combination would form a broad lung cancer franchise. Bloomberg Government reports the deal is expected to add to GSK's sales and core operating profit by 2027.
Industry on a Deal-Making Tear Amid US Tariff Pressures
The Nuvalent acquisition is part of a broader 2026 buying spree across the pharmaceutical industry. The Guardian reports that 40 major biopharma deals have already been announced by June. Companies are rushing to fill drug pipelines as blockbuster products near patent expiration and US pricing pressure mounts.
GSK is not immune to that pressure. In December 2025, the company joined other non-US drugmakers in agreeing to lower prescription prices for American patients to avoid tariffs threatened by the Trump administration, according to BSS News. The Nuvalent deal — centered on two drugs awaiting FDA approval — keeps GSK's growth engine squarely inside the US market.
Sentiment
NeutralPublishers
5
Articles
5
Reach
5
